[ad_1]
Sung H, Ferlay J, Siegel R, Soerjomataram I, Jemal A, Bray F. International most cancers statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 international locations. CA Most cancers J Clin. 2021;71:209–49.
Chu Okay, Dupuy D. Thermal ablation of tumours: organic mechanisms and advances in remedy. Nat Rev Most cancers. 2014;14:199–208.
Yoshida S, Kornek M, Ikenaga N, Schmelzle M, Masuzaki R, Csizmadia E, Wu Y, Robson S, Schuppan D. Warmth therapy promotes epithelial–mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology. 2013;58:1667–80.
Dumolard L, Ghelfi J, Roth G, Decaens T, Macek JZ. Percutaneous ablation-induced immunomodulation in hepatocellular carcinoma. Int J Mol Sci. 2020;21:4398.
Su T, Liao J, Dai Z, Xu L, Chen S, Wang Y, Peng Z, Zhang Q, Peng S, et al. Stress-induced phosphoprotein 1 mediates hepatocellular carcinoma metastasis after inadequate radiofrequency ablation. Oncogene. 2018;37:14–27.
Lam V, Ng Okay, Chok Okay, Cheung T, Yuen J, Tung H, Tso W, Fan S, Poon R. Danger components and prognostic components of native recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg. 2008;207:20–9.
Zhao Z, Wu J, Liu X, Liang M, Zhou X, Ouyang S, Yao L, Wang L, Luo B. Inadequate radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma by way of autophagy. Most cancers Lett. 2018;421:73–81.
Kong J, Kong L, Kong J, Ke S, Gao J, Ding X, Zheng L, Solar H, Solar W. After inadequate radiofrequency ablation, tumor-associated endothelial cells exhibit enhanced angiogenesis and promote invasiveness of residual hepatocellular carcinoma. J Transl Med. 2012;10:230.
Nijkamp M, van der Bilt J, de Bruijn M, Molenaar I, Voest E, van Diest P, Kranenburg O, Borel RI. Accelerated perinecrotic outgrowth of colorectal liver metastases following radiofrequency ablation is a hypoxia-driven phenomenon. Ann Surg. 2009;249:814–23.
Iwahashi S, Shimada M, Utsunomiya T, Imura S, Morine Y, Ikemoto T, Takasu C, Saito Y, Yamada S. Epithelial–mesenchymal transition-related genes are linked to aggressive native recurrence of hepatocellular carcinoma after radiofrequency ablation. Most cancers Lett. 2016;375:47–50.
Tan L, Chen S, Wei G, Li Y, Liao J, Jin H, Zou Y, Huang M, Peng Z, et al. Sublethal warmth therapy of hepatocellular carcinoma promotes intrahepatic metastasis and stemness in a VEGFR1-dependent method. Most cancers Lett. 2019;460:29–40.
Zhang N, Wang L, Li D, Ma D, Wang C, He X, Gao D, Wang L, Tang Z. Interferon-alpha mixed with natural compound “Songyou Yin” successfully inhibits the elevated invasiveness and metastasis by inadequate radiofrequency ablation of hepatocellular carcinoma in an animal mannequin. Integr most cancers ther. 2018;17:1260–9.
Zhang N, Li H, Qin C, Ma D, Zhao Y, Zhu W, Wang L. Inadequate radiofrequency ablation promotes the metastasis of residual hepatocellular carcinoma cells by way of upregulating flotillin proteins. J Most cancers Res Clin Oncol. 2019;145:895–907.
Kong J, Yao C, Ding X, Dong S, Wu S, Solar W, Zheng L. ATPase inhibitory issue 1 promotes hepatocellular carcinoma development after inadequate radiofrequency ablation and attenuates cell sensitivity to sorafenib remedy. Entrance Oncol. 2020;10:1080.
Chen L, Ma X, Liu X, Cui X. Sorafenib mixed with radiofrequency ablation as therapy for sufferers with hepatocellular carcinoma: a scientific overview and meta-analysis. J BUON. 2017;22:1525–32.
Sanz M, Grimwade D, Tallman M, Lowenberg B, Fenaux P, Estey E, Naoe T, Lengfelder E, Dohner H, et al. Administration of acute promyelocytic leukemia: suggestions from an professional panel on behalf of the European LeukemiaNet. Blood. 2009;113:1875–91.
Sadaf N, Kumar N, Ali M, Ali V, Bimal S, Haque R. Arsenic trioxide induces apoptosis and inhibits the expansion of human liver most cancers cells. Life Sci. 2018;205:9–17.
Wei J, Ye C, Liu F, Wang W. All-trans retinoic acid and arsenic trioxide induce apoptosis and modulate intracellular concentrations of calcium in hepatocellular carcinoma cells. J Chemother. 2014;26:348–52.
Wang G, Zhang W, Fang Z, Zhang W, Yang M, Yang G, Li S, Zhu L, Wang L, et al. Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription issue twist in vivo and in vitro. J Most cancers Res Clin Oncol. 2014;140:1125–36.
Huang Y, Zhou B, Luo H, Mao J, Huang Y, Zhang Okay, Mei C, Yan Y, Jin H, et al. ZnAs@SiO2 nanoparticles as a possible anti-tumor drug for concentrating on stemness and epithelial–mesenchymal transition in hepatocellular carcinoma by way of SHP-1/JAK2/STAT3 signaling. Theranostics. 2019;9:4391–408.
Qiu Y, Dai Y, Zhang C, Yang Y, Jin M, Shan W. Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a focused intervention of 14-3-3eta/NF-kappaB suggestions loop. J Exp Clin Most cancers Res. 2018;37:321.
Yu G, Chen X, Chen S, Ye W, Hou Okay, Liang M. Arsenic trioxide reduces chemo-resistance to 5-fluorouracil and cisplatin in HBx-HepG2 cells by way of advanced mechanisms. Most cancers Cell Int. 2015;15:116.
Liu B, Pan S, Dong X, Qiao H, Jiang H, Krissansen G. Opposing results of arsenic trioxide on hepatocellular carcinomas in mice. Most cancers Sci. 2006;97:675–81.
Huang W, Zeng Y. A candidate for lung most cancers therapy: arsenic trioxide. Clin Transl Oncol. 2019;21:1115–26.
Fu X, Liang Q, Luo R, Li Y, Xiao X, Yu L, Shan W, Fan G, Tang Q. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic impact on an aggressive hepatocellular carcinoma mannequin by way of enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment. J Mater Chem B. 2019;7:3088–99.
Wu Q, Chen X, Wang P, Wu Q, Qi X, Han X, Chen L, Meng X, Xu Okay. Supply of arsenic trioxide by multifunction nanoparticles to enhance the therapy of hepatocellular carcinoma. ACS Appl Mater Interfaces. 2020;12:8016–29.
Wang L, Zhang J, An Y, Wang Z, Liu J, Li Y, Zhang D. A examine on the thermochemotherapy impact of nanosized As2O3/MZF thermosensitive magnetoliposomes on experimental hepatoma in vitro and in vivo. Nanotechnology. 2011;22:315102.
Lee S, Lee O, O’Halloran T, Schatz G, Nguyen S. Triggered launch of pharmacophores from [Ni(HAsO3)]-loaded polymer-caged nanobin enhances pro-apoptotic exercise: a mixed experimental and theoretical examine. ACS Nano. 2011;5:3961–9.
Zhao Z, Zhang H, Chi X, Li H, Yin Z, Huang D, Wang X, Gao J. Silica nanovehicles endow arsenic trioxide with a capability to successfully deal with most cancers cells and strong tumors. J Mater Chem B. 2014;2:6313–23.
Wang X, Hu Y, Mo J, Zhang J, Wang Z, Wei W, Li H, Xu Y, Ma J, et al. Arsenene: a possible therapeutic agent for acute promyelocytic leukaemia cells by performing on nuclear proteins. Angew Chem Int Ed Engl. 2020;59:5151–8.
Liu C, Solar S, Feng Q, Wu G, Wu Y, Kong N, Yu Z, Yao J, Zhang X, et al. Arsenene nanodots with selective killing results and their low-dose mixture with ß-elemene for most cancers remedy. Adv Mater. 2021;33: e2102054.
Kong N, Zhang H, Feng C, Liu C, Xiao Y, Zhang X, Mei L, Kim J, Tao W, et al. Arsenene-mediated a number of independently focused reactive oxygen species burst for most cancers remedy. Nat Commun. 2021;12:4777.
Panahi Y, Farshbaf M, Mohammadhosseini M, Mirahadi M, Khalilov R, Saghfi S, Akbarzadeh A. Latest advances on liposomal nanoparticles: synthesis, characterization and biomedical functions. Artif Cells Nanomed Biotechnol. 2017;45:788–99.
Yang J, Yang Y. Steel-organic frameworks for biomedical functions. Small. 2020;16: 1906846.
Mao H, Xu J, Hu Y, Huang Y, Tune Y. The impact of excessive exterior stress on the construction and stability of MOF a-Mg3(HCOO)6 probed by in situ Raman and FT-IR spectroscopy. J Mater Chem A. 2015;3:11976–84.
Meng J, Li J, Liu J, Zhang X, Jiang G, Ma L, Hu Z, Xi S, Zhao Y, et al. Common strategy to fabricating graphene-supported single-atom catalysts from doped ZnO strong options. ACS Cent Sci. 2020;6:1431–40.
Meng J, Liu Z, Liu X, Yang W, Wang L, Li Y, Cao Y, Zhang X, Mai L. Scalable fabrication and energetic web site identification of MOF shell-derived nitrogen-doped carbon hole frameworks for oxygen discount. J Mater Sci Technol. 2021;66:186–92.
Meng J, He Q, Xu L, Zhang X, Liu F, Wang X, Li Q, Xu X, Zhang G, et al. Identification of part management of carbon-confined Nb2O5 nanoparticles towards high-performance lithium storage. Adv Vitality Mater. 2019;9:1802695.
Li J, Tune S, Meng J, Tan L, Liu X, Zheng Y, Li Z, Yeung Okay, Cui Z, et al. 2D MOF periodontitis photodynamic ion remedy. J Am Chem Soc. 2021;143:15427–39.
Gao L, Chen Q, Gong T, Liu J, Li C. Latest development of imidazolate framework (ZIF-8) primarily based nanoformulations for synergistic tumor remedy. Nanoscale. 2019;11:21030–45.
Zheng H, Zhang Y, Liu L, Wan W, Guo P, Nyström A, Zou X. One-pot synthesis of metallic–natural frameworks with encapsulated goal molecules and their functions for managed drug supply. J Am Chem Soc. 2016;138:962–8.
Yan J, Liu C, Wu Q, Zhou J, Xu X, Zhang L, Wang D, Yang F, Zhang H. Mineralization of pH-sensitive doxorubicin prodrug in ZIF-8 to allow focused supply to strong tumors. Anal Chem. 2020;92:11453–61.
Zhuang J, Kuo C, Chou L, Liu D, Weerapana E, Tsung C. Optimized metal-organic-framework nanospheres for drug supply: analysis of small-molecule encapsulation. ACS Nano. 2014;8:2812–9.
Zhang Y, Kohler N, Zhang M. Floor modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials. 2002;23:1553–61.
Parekh G, Shi Y, Zheng J, Zhang X, Leporatti S. Nano-carriers for focused supply and biomedical imaging enhancement. Ther Deliv. 2018;9:451–68.
Chen T, Yi J, Zhao Y, Chu X. Biomineralized metallic–natural framework nanoparticles allow intracellular supply and endo-lysosomal launch of native energetic proteins. J Am Chem Soc. 2018;140:9912–20.
Wang H, Chen Y, Wang H, Liu X, Zhou X, Wang F. DNAzyme-loaded metallic–natural frameworks (MOFs) for self-sufficient gene remedy. Angew Chem Int Ed Engl. 2019;58:7380–4.
Schnabel J, Ettlinger R, Bunzen H. Zn-MOF-74 as pH-responsive drug-delivery system of arsenic trioxide. Chem Nano Mat. 2020;6:1229–36.
Tao W, Zhu X, Yu X, Zeng X, Xiao Q, Zhang X, Ji X, Wang X, Shi J, et al. Black phosphorus nanosheets as a strong supply platform for most cancers theranostics. Adv Mater. 2017;29:1603276.
Martinson C, Reddy Okay. Adsorption of arsenic(III) and arsenic(V) by cupric oxide nanoparticles. J Colloid Interface Sci. 2009;336:406–11.
Poch F, Rieder C, Ballhausen H, Knappe V, Ritz J, Gemeinhardt O, Kreis M, Lehmann Okay. The vascular cooling impact in hepatic multipolar radiofrequency ablation results in incomplete ablation ex vivo. Int J Hyperth. 2016;32:749–56.
Berber E, Siperstein A. Native recurrence after laparoscopic radiofrequency ablation of liver tumors: an evaluation of 1032 tumors. Ann Surg Oncol. 2008;15:2757–64.
Lencioni R. Loco-regional therapy of hepatocellular carcinoma. Hepatology. 2010;52:762–73.
Kim Okay, Lee J, Klotz E, Kim S, Kim S, Kim J, Han J, Choi B. Security margin evaluation after radiofrequency ablation of the liver utilizing registration of preprocedure and postprocedure CT photographs. AJR Am J Roentgenol. 2011;196:565–72.
Dongre A, Weinberg R. New insights into the mechanisms of epithelial–mesenchymal transition and implications for most cancers. Nat Rev Mol Cell Biol. 2019;20:69–84.
Fang J, Islam W, Maeda H. Exploiting the dynamics of the EPR impact and techniques to enhance the therapeutic results of nanomedicines by utilizing EPR impact enhancers. Adv Drug Deliv Rev. 2020;157:142–60.
Ojha T, Pathak V, Shi Y, Hennink W, Moonen C, Storm G, Kiessling F, Lammers T. Pharmacological and bodily vessel modulation methods to enhance EPR-mediated drug concentrating on to tumors. Adv Drug Deliv Rev. 2017;119:44–60.
Xu M, Hu Y, Ding W, Li F, Lin J, Wu M, Wu J, Wen L, Qiu B, et al. Rationally designed rapamycin-encapsulated ZIF-8 nanosystem for overcoming chemotherapy resistance. Biomaterials. 2020;258: 120308.
Franklin R, Levy B, Zou J, Hanna N, Desouki M, Bagasra O, Johnson L, Costello L. ZIP14 zinc transporter downregulation and zinc depletion within the growth and development of hepatocellular most cancers. J Gastrointest Most cancers. 2012;43:249–57.
Xue Y, Yu B, Liu Y, Guo R, Li J, Zhang L, Su J, Solar L, Li Y. Zinc promotes prostate most cancers cell chemosensitivity to paclitaxel by inhibiting epithelial–mesenchymal transition and inducing apoptosis. Prostate. 2019;79:647–56.
Hosui A, Kimura E, Abe S, Tanimoto T, Onishi Okay, Kusumoto Y, Sueyoshi Y, Matsumoto Okay, Hirao M, et al. Lengthy-term zinc supplementation improves liver operate and reduces the danger of growing hepatocellular carcinoma. Vitamins. 2018;10:1955.
[ad_2]
